Day: April 2, 2024

Conference Call and Webcast Today at 8:30 a.m. ETReceived alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (RMAT) designation granted by FDA to OCU400 Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectivelyMALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today provided a general business update with certain financials for the year ending 2023. “In...

Company Provides Corporate Update that Include Updates on its Investigational Fully Implanted Acclaim® Cochlear Implant Meeting its Early Feasibility Study Milestones Recent bipartisan Congressional bill, the Hearing Device Coverage Clarification Act, seeks to open a pathway to insurance coverage for the Company’s Esteem® Fully Implanted Active Middle Ear Implant WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) — Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023. Financial and Corporate Highlights from Q4 2023 to DateCompleted Business Combination transaction at the end of September and began trading on Nasdaq under...

2023 net revenue of $2.83M, up 276% versus prior year due to major retailer engagements BEND, Ore., April 02, 2024 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF), a pioneering food technology company and producer of dehydrated fruit and vegetable-based products, today announced its recent accomplishments and financial results for the fourth quarter and year ended December 31, 2023. Eric Healy, CEO of BranchOut Foods, said, “We are very pleased with BranchOut Food’s significant growth and accomplishments since our IPO in June 2023. In the ensuing nine months, we have built strong, long-term relationships with some of the nation’s leading retailers, and our products have now established popularity among shoppers in stores throughout the country. “The fourth quarter was marked by revenue nearly doubling that of the previous...

NAPLES, Fla., April 02, 2024 (GLOBE NEWSWIRE) — via IBN – HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare networking and technological innovation, announced its financial results for the fourth quarter and full year ended December 31, 2023. With strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth. Full Year 2023 Financial Results Strategic Focus and Technological Innovations Pave the Way for an Optimistic Outlook: HealthLynked reported a modest 2% revenue decrease to $5.72 million, attributed in part to the retirement of, and contracts ending for, certain key physicians and the onboarding phase of new physicians...

Revenue Continues to Accelerate, Increasing 53% in First Half of FY2024 DALLAS, April 02, 2024 (GLOBE NEWSWIRE) — Blackboxstocks Inc. (NASDAQ: BLBX), (“Blackbox” or the “Company”), a financial technology and social media hybrid platform offering real-time proprietary analytics for stock and options traders of all levels, today released financial results for the first half of FY2024 ended December 31, 2023, for its acquisition target company, Evtec Aluminum.Revenue for the twelve months of FY 2023 reached $30.9 million compared to $14.4 million for FY2022 ended June 30, 2022, an increase of 115%.Revenue for the first half of fiscal 2024 was $21.3 million, an increase of 53% compared to $13.9 million for the first half of fiscal 2023, ended December 31, 2022.Total projected revenue for FY 2024 ending June 30, 2024, is expected...